Race and Ethnicity in Lewy Body Dementia: A Narrative Review
- PMID: 37355902
- PMCID: PMC10448838
- DOI: 10.3233/JAD-230207
Race and Ethnicity in Lewy Body Dementia: A Narrative Review
Abstract
Lewy body dementia is the third most common and costliest type of dementia. It is an umbrella term for dementia with Lewy bodies and Parkinson's disease dementia, both of which place a substantial burden on the person and society. Recent findings outline ethnoracial differences in dementia risk. Delayed and misdiagnosis across ethnoracial groups contribute to higher levels of burden. In this context, we aimed to summarize current knowledge, gaps, and unmet needs relating to race and ethnicity in Lewy body dementia. In this narrative review, we provide an overview of studies on Lewy body dementia focusing on differences across ethnoracial groups and outline several recommendations for future studies. The majority of the findings comparing different ethnoracial groups were from North American sites. There were no differences in clinical prevalence and progression across ethnoracial groups. Compared to people identifying as non-Hispanic White, co-pathologies were more common and clinical diagnostic accuracy was lower for people identifying as Black. Co-morbidities (e.g., diabetes, hypertension) were more common and medication use rates (e.g., antidepressants, antiparkinsonian agents) were lower for people identifying as Black or Hispanic compared to people identifying as White. More than 90% of clinical trial participants identified as non-Hispanic White. Despite increasing efforts to overcome disparities in Alzheimer's disease and related dementias, inclusion of individuals from minoritized communities in Lewy body dementia studies continues to be limited and the findings are inconclusive. Representation of diverse populations is crucial to improve the diagnostic and therapeutic efforts in Lewy body dementia.
Keywords: Alzheimer’s disease; Lewy body disease; dementia; diversity; equity; ethnicity; inclusion; racial groups.
Conflict of interest statement
CONFLICT OF INTEREST
Dr. Armstrong serves on the Data and Safety Monitoring Boards for the Alzheimer’s Therapeutic Research Institute/Alzheimer’s Clinical Trial Consortium and the Alzheimer’s Disease Cooperative Study. She has provided educational content for Medscape. The authors have no other conflict of interest to report.
Figures
Similar articles
-
Neuropathological and Clinical Correlates of Lewy Body Disease Survival by Race and Ethnicity in the National Alzheimer's Coordinating Center.J Alzheimers Dis. 2022;89(4):1339-1349. doi: 10.3233/JAD-220297. J Alzheimers Dis. 2022. PMID: 36031892 Free PMC article.
-
Clinical presentation and differential diagnosis of dementia with Lewy bodies: a review.Int J Geriatr Psychiatry. 2014 Jun;29(6):569-76. doi: 10.1002/gps.4039. Epub 2013 Oct 21. Int J Geriatr Psychiatry. 2014. PMID: 24150834 Review.
-
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X. Lancet Neurol. 2011. PMID: 21317042
-
Prevalence and clinical associations of tau in Lewy body dementias: A systematic review and meta-analysis.Parkinsonism Relat Disord. 2020 Nov;80:184-193. doi: 10.1016/j.parkreldis.2020.09.030. Epub 2020 Sep 23. Parkinsonism Relat Disord. 2020. PMID: 33260030
-
Assessment of genetic risk for improved clinical-neuropathological correlations.Acta Neuropathol Commun. 2020 Sep 10;8(1):160. doi: 10.1186/s40478-020-01033-1. Acta Neuropathol Commun. 2020. PMID: 32912321 Free PMC article.
Cited by
-
Under-Diagnosis of Dementia with Lewy Bodies in Individuals Racialized as Black: Hypotheses Regarding Potential Contributors.J Alzheimers Dis. 2024;97(4):1571-1580. doi: 10.3233/JAD-231177. J Alzheimers Dis. 2024. PMID: 38277299 Free PMC article. Review.
-
End-of-Life Healthcare Utilization in Lewy Body Dementia.J Alzheimers Dis. 2024;101(1):133-145. doi: 10.3233/JAD-240194. J Alzheimers Dis. 2024. PMID: 39121116 Free PMC article.
-
Lewy body dementia: Overcoming barriers and identifying solutions.Alzheimers Dement. 2024 Mar;20(3):2298-2308. doi: 10.1002/alz.13674. Epub 2024 Jan 24. Alzheimers Dement. 2024. PMID: 38265159 Free PMC article.
-
Examining the lived experience of dementia with Lewy bodies through qualitative research: A systematic review.Alzheimers Dement. 2025 May;21(5):e70217. doi: 10.1002/alz.70217. Alzheimers Dement. 2025. PMID: 40371732 Free PMC article.
-
Plasma phosphorylated tau and neuropsychiatric symptoms in dementia with Lewy bodies.Alzheimers Dement. 2025 Feb;21(2):e14434. doi: 10.1002/alz.14434. Epub 2024 Dec 28. Alzheimers Dement. 2025. PMID: 39732510 Free PMC article.
References
-
- Vann Jones SA, O’Brien JT (2014) The prevalence and incidence of dementia with Lewy bodies: A systematic review of population and clinical studies. Psychol Med 44, 673–683. - PubMed
-
- Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 20, 1255–1263. - PubMed
-
- Palmqvist S, Hansson O, Minthon L, Londos E (2009) Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer’s disease with common cognitive tests. Int J Geriatr Psychiatry 24, 1405–1412. - PubMed